{"id":"95d033dd1f7e","type":"article","url":"https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/","title":"Contractiliteitssensor-geleide CRT-optimalisatie: RESPOND-CRT-trial","title_en":"Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["cardiale-resynchronisatie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehw526","source_url":"https://doi.org/10.1093/eurheartj/ehw526","authors":["Josep Brugada","Peter Paul Delnoy","Johannes Brachmann","Dwight Reynolds","Luigi Padeletti","Georg Noelker","Charan Kantipudi","José Manuel Rubin Lopez","Wolfgang Dichtl","Alberto Borri-Brunetto","Luc Verhees","Philippe Ritter","Jagmeet P Singh"],"significance":6,"published":"2017-03-07","source_date":"2017-03-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/crt-cardiale-resynchronisatietherapie/"],"congress":"","summary_en":"The RESPOND-CRT trial evaluated contractility sensor-guided CRT optimization, testing whether individualized AV and VV delay programming using a sensor-based algorithm improves response rates in heart failure patients.","created":"2026-07-03T10:26:35Z","updated":"2026-07-03T13:25:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"RESPOND-CRT-trial naar optimalisatie van cardiale resynchronisatietherapie met een contractiliteitssensor. Onderzocht of individuele hemodynamische optimalisatie de CRT-respons verbetert.","abstract_original":"AIMS: Although cardiac resynchronization therapy (CRT) is effective in patients with systolic heart failure (HF) and a wide QRS interval, a substantial proportion of patients remain non-responsive. The SonR contractility sensor embedded in the right atrial lead enables individualized automatic optimization of the atrioventricular (AV) and interventricular (VV) timings. The RESPOND-CRT study investigated the safety and efficacy of the contractility sensor system in HF patients undergoing CRT. METHODS AND RESULTS: RESPOND-CRT was a prospective, randomized, double-blinded, multicentre, non-inferiority trial. Patients were randomized (2:1, respectively) to receive weekly, automatic CRT optimization with SonR vs. an Echo-guided optimization of AV and VV timings. The primary efficacy endpoint was the rate of clinical responders (patients alive, without adjudicated HF-related events, with improvement in New York Heart Association class or quality of life), at 12 months. The study randomized 998 patients. Responder rates were 75.0% in the SonR arm and 70.4% in the Echo arm (mean difference, 4.6%; 95% CI, -1.4% to 10.6%; P < 0.001 for non-inferiority margin -10.0%) (Table 2). At an overall mean follow-up of 548 ± 190 days SonR was associated with a 35% risk reduction in HF hospitalization (hazard ratio, 0.65; 95% CI, 0.46-0.92; log-rank P = 0.01). CONCLUSION: Automatic AV and VV optimization using the contractility sensor was safe and as effective as Echo-guided AV and VV optimization in increasing response to CRT. CLINICALTRIALS.GOV NUMBER: NCT01534234."}